Trexquant Investment LP Takes $405,000 Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Trexquant Investment LP bought a new stake in Kodiak Sciences Inc. (NASDAQ:KOD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 40,736 shares of the company’s stock, valued at approximately $405,000. Trexquant Investment LP owned 0.08% of Kodiak Sciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of KOD. State Street Corp grew its position in Kodiak Sciences by 1.8% during the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock worth $2,131,000 after purchasing an additional 14,711 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Kodiak Sciences by 1.7% during the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock worth $2,007,000 after buying an additional 12,783 shares during the period. FMR LLC grew its holdings in shares of Kodiak Sciences by 26.4% during the third quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after buying an additional 41,987 shares during the last quarter. Peapod Lane Capital LLC acquired a new position in Kodiak Sciences in the 4th quarter valued at about $1,660,000. Finally, JPMorgan Chase & Co. raised its stake in Kodiak Sciences by 194.9% during the 4th quarter. JPMorgan Chase & Co. now owns 131,646 shares of the company’s stock valued at $1,310,000 after acquiring an additional 86,998 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Up 3.8 %

Shares of NASDAQ:KOD opened at $2.18 on Friday. Kodiak Sciences Inc. has a fifty-two week low of $1.92 and a fifty-two week high of $11.60. The firm’s 50-day simple moving average is $3.71 and its 200-day simple moving average is $5.38. The company has a market cap of $114.99 million, a price-to-earnings ratio of -0.60 and a beta of 2.40.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06. On average, research analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating and issued a $3.00 target price on shares of Kodiak Sciences in a research note on Monday, March 31st.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.